Other languages Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Equities

DUL

US02043Q1076

Market Closed - Börse Stuttgart Other stock markets 03:22:02 2024-07-16 pm EDT			5-day change	1st Jan Change
229.9 ^EUR	-2.75%		+0.47%	+34.62%

Jul. 15	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing	MT
Jul. 03	Jerome Powell did it again

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing	Jul. 15
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU : Alphabet, Nike, Nvidia, Tesla, Starbucks...	Jul. 03
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing	Jun. 26
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing	Jun. 26
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing	Jun. 26
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing	Jun. 26
Sector Update: Health Care Stocks Ease Late Afternoon	Jun. 25
Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study	Jun. 25
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...	Jun. 25
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Jun. 24
Top Midday Gainers	Jun. 24
Los resultados del fármaco de Alnylam Pharmaceutical se consideran el "mejor escenario posible" -- Market Talk	Jun. 24
Alnylam Pharmaceuticals Says Heart Disease Therapy Meets Primary Endpoint in Late-Stage Study	Jun. 24
Alnylam's heart disease drug meets main goal in late-stage study	Jun. 24
Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations	Jun. 24
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,224,546, According to a Recent SEC Filing	Jun. 03
Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed	May. 02
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024	May. 02
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia	Apr. 30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Equities

DUL

US02043Q1076

Other languages

Filters